Cargando…

Off-Label Antipsychotic Prescribing for Persons With Dementia in Assisted Living

Off-label antipsychotic use is contra-indicated for persons with dementia due to lack of efficacy and FDA black box warnings. Yet, residents in assisted living (AL), including those with dementia, are frequently prescribed such medications. If distinct typologies of AL communities exist based on pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wretman, Christopher, Zimmerman, Sheryl, Sloane, Philip, Preisser, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7742250/ http://dx.doi.org/10.1093/geroni/igaa057.2483

Ejemplares similares

Antipsychotic and Psychotropic Prescribing in Assisted Living
por: Zimmerman, Sheryl, et al.
Publicado: (2020)

Potential Antipsychotic Side Effects and Adverse Events of Assisted Living Residents With Dementia
por: Beeber, Anna, et al.
Publicado: (2020)

Implementing Psychosocial and Environmental Practices for Persons With Dementia in Assisted Living
por: Schwartz, Lindsay, et al.
Publicado: (2020)

Melatonin Use for Sleep in Assisted Living
por: Peketi, Punita, et al.
Publicado: (2020)

Which Assisted Living Communities Provide Hospice?
por: Prizer, Lindsay, et al.
Publicado: (2020)

Potential Side Effects and Adverse Events of Antipsychotic Use for Residents With Dementia in Assisted Living: Implications for Prescribers, Staff, and Families
por: Beeber, Anna Song, et al.
Publicado: (2021)

Local Nursing Home Prescribing Patterns and Psychoactive Prescribing in Assisted Living
por: Thomas, Kali, et al.
Publicado: (2020)

Psychoactive Prescribing in Assisted Living
por: Zimmerman, Sheryl, et al.
Publicado: (2020)

Pro Re Nata Use of Psychotropic Medications in Assisted Living
por: Carder, Paula, et al.
Publicado: (2020)

Seven-State Study of Assisted Living and Healthcare Providers’ Responses to COVID-19
por: Zimmerman, Sheryl, et al.
Publicado: (2021)

EXPERT CONSENSUS PANEL RECOMMENDATIONS FOR MEDICAL AND MENTAL HEALTH CARE IN ASSISTED LIVING
por: Zimmerman, Sheryl, et al.
Publicado: (2022)

Assisted Living Care for Special Populations
por: Sloane, Philip, et al.
Publicado: (2020)

COVID-19 Recommendations for Assisted Living: Implications for the Future
por: Vipperman, Andrew, et al.
Publicado: (2021)

Off-label prescribing of antipsychotics: prescribing practices and clinical experiences of Finnish physicians
por: Rautio, N., et al.
Publicado: (2022)

Excess Mortality Attributable to COVID-19 Among Assisted Living Residents
por: Thomas, Kali, et al.
Publicado: (2021)

A Typology of Health Services Regulated in U.S. Assisted Living Communities
por: Carder, Paula, et al.
Publicado: (2021)

Effectiveness of a Mouth Care Program Provided by Nursing Home Staff vs Standard Care on Reducing Pneumonia Incidence: A Cluster Randomized Trial
por: Zimmerman, Sheryl, et al.
Publicado: (2020)

Medical and Mental Health Care Challenges in Nursing Homes, Assisted Living, and Programs of All-Inclusive Care for the Elderly (PACE) During COVID-19
por: Zimmerman, Sheryl, et al.
Publicado: (2022)

How Assisted Living Staff Conceive of Dementia Care
por: Dobbs, Debra, et al.
Publicado: (2020)

COVID-19 Perspectives of Assisted Living and Health Care Providers in Seven States
por: Zimmerman, Sheryl, et al.
Publicado: (2021)

Off-label use of atypical antipsychotics- Where are we?
por: Vaz, R. P., et al.
Publicado: (2023)

COVID-19 Recommendations for Assisted Living: Implications for the Future
por: Vipperman, Andrew, et al.
Publicado: (2021)

REIMAGINING THE FUTURE OF ASSISTED LIVING TO PROMOTE QUALITY
por: Zimmerman, Sheryl
Publicado: (2022)

Antipsychotic prescribing in dementia
por: McLoughlin, James, et al.
Publicado: (2021)

The Need for Person-Centered Measures for Dementia Research and Care
por: Fazio, Sam, et al.
Publicado: (2021)

REIMAGINING POLICY-INFORMED RESEARCH FOR THE FUTURE OF ASSISTED LIVING
por: Carder, Paula, et al.
Publicado: (2022)

Prescribing of Antipsychotic Medication in a Medicaid Population: Use of Polytherapy and Off-Label Dosages
por: Kogut, Stephen J., et al.
Publicado: (2005)

Antipsychotics in elderly people: to prescribe or to ban?
por: Zbidi, M., et al.
Publicado: (2023)

State Variability in Assisted Living Regulations, Access, and Outcomes for Persons With Dementia
por: Thomas, Kali
Publicado: (2020)

Nontraditional Small House Nursing Homes Have Fewer COVID-19 Cases and Deaths
por: Zimmerman, Sheryl, et al.
Publicado: (2021)

Antipsychotics and dementia
por: Gareri, P, et al.
Publicado: (2010)

Group Music Intervention for Persons With Dementia in Assisted Living: A Pilot Study
por: Meng, Hongdao, et al.
Publicado: (2020)

The Need to Include Assisted Living in Responding to the COVID-19 Pandemic
por: Zimmerman, Sheryl, et al.
Publicado: (2020)

A VISION FOR THE FUTURE OF ASSISTED LIVING RESEARCH: LEVERAGING ADMINISTRATIVE DATA TO STUDY QUALITY
por: Thomas, Kali, et al.
Publicado: (2022)

Measurement for Something as Personal as Dressing is Not Personalized
por: Prizer, Lindsay, et al.
Publicado: (2021)

Antipsychotics in off-label use: prescription practices, benefits and risks Results from APSY Oulu study
por: Jääskeläinen, E.
Publicado: (2023)

COVID-19 Response In U.S. Assisted Living Settings: Key Stakeholder Perspectives
por: Dys, Sarah, et al.
Publicado: (2021)

Antipsychotic prescribing choices in patients with First Episode Psychosis
por: Fallon, J., et al.
Publicado: (2022)

Estimation of Excess Mortality Rates Among US Assisted Living Residents During the COVID-19 Pandemic
por: Thomas, Kali S., et al.
Publicado: (2021)

“Doing the Impossible with the Inadequate”: COVID-19 Response in U.S. Assisted Living Settings
por: Dys, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_leui9bccs23nsr0ukvt33bnk2d